Organisation paid for research Program year 2025 Source: CMS Open Payments

Atrium Health Cabarrus

Neither a doctor nor a teaching hospital

Research payments

$128,266

13 payments

Through program year 2025, Atrium Health Cabarrus is reported as receiving $128,266 in research payments, across 13 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$29,033	7
2023	Research	$837	1
2020	Research	$98,396	5

Breakdown

Who paid Research payments · program years 2020–2025

Celgene Corporation $98,396 5 payments
Amgen Inc. $29,033 7 payments
E.R. Squibb & Sons, L.L.C. $837 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma $49,356 1 payment
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) $17,300 2 payments
A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM) $16,500 1 payment
PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) (BMS Study Number: IM047-P14) $12,385 1 payment
Ph III Yellowstone CD Maintenance (RPC01-3203) (BMS Study Number: IM047-P16) $10,995 1 payment
Ph III Yellowstone CD OLE (RPC01-3204) (BMS Study Number: IM047-P17) $9,160 1 payment
Ph 4 Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving KRYSTEXXA $6,675 1 payment
A Phase 1b, Open-label, Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Subjects With High-risk Biochemical Recurrence of Nonmetastatic Castration-sensitive Prostate Cancer After Definitive Therapy $5,010 2 payments
Phase 2 CD (Primary represents Induction) - A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohns Disease $837 1 payment
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Chemotherapy $26 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.